China Healthwise Holdings Full Year 2024 Earnings: HK$0.052 loss per share (vs HK$0.17 loss in FY 2023)

Simply Wall St

April 02, 2025

China Healthwise Holdings (HKG:348) Full Year 2024 Results

Key Financial Results

Revenue: HK$113.6m (down 22% from FY 2023).
Net loss: HK$40.3m (loss narrowed by 70% from FY 2023).
HK$0.052 loss per share (improved from HK$0.17 loss in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

earnings-and-revenue-history — SEHK:348 Earnings and Revenue History April 2nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

China Healthwise Holdings shares are down 12% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 4 warning signs for China Healthwise Holdings (3 are a bit concerning!) that you need to be mindful of.

If you're looking to trade China Healthwise Holdings, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.